All Stories

  1. Long-term outcomes with initial triple oral therapy in pulmonary arterial hypertension (PAH): Insights from TRITON
  2. Severe Pulmonary Hypertension Management Across Europe (PHAROS): an ERS Clinical Research Collaboration
  3. Initial combination therapy of macitentan and tadalafil in pulmonary arterial hypertension
  4. Pulmonary arterial hypertension registries: past, present and into the future
  5. Intensity and quality of exertional dyspnoea in patients with stable pulmonary hypertension
  6. A dynamic prognostic model to predict survival and determine treatment goals in pulmonary arterial hypertension (PAH): the EFORT study
  7. Assembly 13: placing the pulmonary circulation in the heart of ERS
  8. Highlights from the ERS International Congress 2018: Assembly 13 – Pulmonary Vascular Diseases
  9. Clinical trial design and new therapies for pulmonary arterial hypertension
  10. Hépatopathies et maladies vasculaires pulmonaires
  11. Clinical and Hemodynamic Correlates of Pulmonary Arterial Stiffness in Incident, Untreated Patients With Idiopathic Pulmonary Arterial Hypertension
  12. Association Between BMI and Obesity With Survival in Pulmonary Arterial Hypertension
  13. Impact of the initiation of balloon pulmonary angioplasty program on referral of patients with chronic thromboembolic pulmonary hypertension to surgery
  14. Risk stratification in pulmonary arterial hypertension
  15. Évaluation de l’IRM cardiaque dans le suivi des patients ayant une hypertension artérielle pulmonaire (EVITA). IRM cardiaque dans le suivi de l’hypertension artérielle pulmonaire
  16. Pulmonary hypertension associated with neurofibromatosis type 1
  17. Natural History over 8 Years of Pulmonary Vascular Disease in a Patient Carrying Biallelic EIF2AK4 Mutations
  18. Pharmacovigilance in a rare disease: example of the VIGIAPATH program in pulmonary arterial hypertension
  19. Portopulmonary hypertension
  20. Factors predicting outcome after pulmonary endarterectomy
  21. Genetic determinants of risk and survival in pulmonary arterial hypertension
  22. Clinical phenotypes and survival of pre-capillary pulmonary hypertension in systemic sclerosis
  23. Age, risk and outcomes in idiopathic pulmonary arterial hypertension
  24. Pulmonary vascular remodeling patterns and expression of general control nonderepressible 2 (GCN2) in pulmonary veno-occlusive disease
  25. The Low-Risk Profile in Pulmonary Arterial Hypertension. Time for a Paradigm Shift to Goal-oriented Clinical Trial Endpoints?
  26. Outcome of Portopulmonary Hypertension After Liver Transplantation
  27. Association between six-minute walk distance and long-term outcomes in patients with pulmonary arterial hypertension: Data from the randomized SERAPHIN trial
  28. Risk assessment in pulmonary arterial hypertension
  29. Temporary treatment interruptions with oral selexipag in pulmonary arterial hypertension: Insights from the Prostacyclin (PGI 2 ) Receptor Agonist in Pulmonary Arterial Hypertension (GRIPHON) study
  30. Prognostic Value of Follow-Up Hemodynamic Variables After Initial Management in Pulmonary Arterial Hypertension
  31. RV Fractional Area Change and TAPSE as Predictors of Severe Right Ventricular Dysfunction in Pulmonary Hypertension: A CMR Study
  32. Pulmonary Arterial Hypertension-Related Morbidity Is Prognostic for Mortality
  33. La maladie veino-occlusive pulmonaire
  34. Targeting the Prostacyclin Pathway with Selexipag in Patients with Pulmonary Arterial Hypertension Receiving Double Combination Therapy: Insights from the Randomized Controlled GRIPHON Study
  35. Association between Rheumatoid Arthritis and Pulmonary Hypertension: Data from the French Pulmonary Hypertension Registry
  36. Pulmonary Arterial Hypertension Associated With Systemic Lupus Erythematosus
  37. Acute decompensated pulmonary hypertension
  38. Dead-space ventilation is linked to exercise capacity and survival in distal chronic thromboembolic pulmonary hypertension
  39. Management and long-term outcomes of sarcoidosis-associated pulmonary hypertension
  40. Medical Treatment of Pulmonary Arterial Hypertension
  41. Portopulmonary Hypertension
  42. Exertional dyspnoea in pulmonary arterial hypertension
  43. Are indexed values better for defining exercise pulmonary hypertension?
  44. Plasma proteome analysis in patients with pulmonary arterial hypertension: an observational cohort study
  45. Risk assessment, prognosis and guideline implementation in pulmonary arterial hypertension
  46. Selexipag for the treatment of connective tissue disease-associated pulmonary arterial hypertension
  47. Impact of High-Priority Allocation on Lung and Heart-Lung Transplantation for Pulmonary Hypertension
  48. Long-term outcomes of dasatinib-induced pulmonary arterial hypertension: a population-based study
  49. Validation of a risk assessment instrument for pulmonary arterial hypertension
  50. Pulmonary hypertension due to left heart disease
  51. Outcome of adults with Eisenmenger syndrome treated with drugs specific to pulmonary arterial hypertension: A French multicentre study
  52. Long-term outcomes of pulmonary arterial hypertension under specific drug therapy in Eisenmenger syndrome
  53. Ambrisentan use for pulmonary arterial hypertension in a post-authorization drug registry: The VOLibris Tracking Study
  54. Long-term outcome in liver transplantation candidates with portopulmonary hypertension
  55. Gut–Lung Connection in Pulmonary Arterial Hypertension
  56. SERAPHIN haemodynamic substudy: the effect of the dual endothelin receptor antagonist macitentan on haemodynamic parameters and NT-proBNP levels and their association with disease progression in patients with pulmonary arterial hypertension
  57. Clinical phenotypes and outcomes of heritable and sporadic pulmonary veno-occlusive disease: a population-based study
  58. Epoprostenol and pulmonary arterial hypertension: 20 years of clinical experience
  59. Macitentan Improves Health-Related Quality of Life for Patients With Pulmonary Arterial Hypertension
  60. Proceedings of Réanimation 2017, the French Intensive Care Society International Congress
  61. A Clinical and Echocardiographic Score to Identify Pulmonary Hypertension Due to HFpEF
  62. Beyond a single pathway: combination therapy in pulmonary arterial hypertension
  63. BMPR2mutation status influences bronchial vascular changes in pulmonary arterial hypertension
  64. Deterioration of pulmonary hypertension and pleural effusion with bosutinib following dasatinib lung toxicity
  65. Interferon-induced pulmonary hypertension
  66. Pulmonary arterial hypertension in idiopathic inflammatory myopathies
  67. Non-invasive diagnosis of pulmonary hypertension from lung Doppler signal: a proof of concept study
  68. Dasatinib induces lung vascular toxicity and predisposes to pulmonary hypertension
  69. Direct-Acting Antiviral Medications for Hepatitis C Virus Infection and Pulmonary Arterial Hypertension
  70. International Liver Transplant Society Practice Guidelines
  71. Regulatory T Cell Dysfunction in Idiopathic, Heritable and Connective Tissue-Associated Pulmonary Arterial Hypertension
  72. Lung capillary blood volume and membrane diffusion in precapillary pulmonary hypertension
  73. Response to Letter Regarding Article, “Mitomycin-Induced Pulmonary Veno-Occlusive Disease: Evidence From Human Disease and Animal Model”
  74. Diagnostic concordance of different criteria for exercise pulmonary hypertension in subjects with normal resting pulmonary artery pressure
  75. Pulmonary veno-occlusive disease
  76. Initial dual oral combination therapy in pulmonary arterial hypertension
  77. Resting pulmonary artery pressure of 21–24 mmHg predicts abnormal exercise haemodynamics
  78. A rare case of sarcoidosis-associated pulmonary hypertension in a patient exposed to silica
  79. Patients’, relatives’, and practitioners’ views of pulmonary arterial hypertension: A qualitative study
  80. BMPR2 mutations and survival in pulmonary arterial hypertension: an individual participant data meta-analysis
  81. Loss of Vascular Distensibility During Exercise Is an Early Hemodynamic Marker of Pulmonary Vascular Disease
  82. Comparative Safety and Tolerability of Prostacyclins in Pulmonary Hypertension
  83. Kinetics of Cardiac Output at the Onset of Exercise in Precapillary Pulmonary Hypertension
  84. Infections liées aux cathéters veineux centraux tunnélisés chez les patients ayant une hypertension artérielle pulmonaire traitée par prostacycline intraveineuse
  85. Selexipag for the Treatment of Pulmonary Arterial Hypertension
  86. Genetic counselling in a national referral centre for pulmonary hypertension
  87. Usefulness of Cardiovascular Magnetic Resonance Indices to Rule In or Rule Out Precapillary Pulmonary Hypertension
  88. Chronic thromboembolic pulmonary hypertension
  89. Pulmonary arterial hypertension in patients treated with interferon: TABLE 1
  90. Occupational exposure to organic solvents: a risk factor for pulmonary veno-occlusive disease
  91. Pulmonary Hypertension Complicating Fibrosing Mediastinitis
  92. Incident and prevalent cohorts with pulmonary arterial hypertension: insight from SERAPHIN
  93. The 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: a practical chronicle of progress
  94. Response to Letter Regarding Article, “Advances in Therapeutic Interventions for Patients With Pulmonary Arterial Hypertension”
  95. Mitomycin-Induced Pulmonary Veno-Occlusive Disease
  96. A prospective study of the 6 min walk test as a surrogate marker for haemodynamics in two independent cohorts of treatment-naïve systemic sclerosis-associated pulmonary arterial hypertension
  97. New pharmacotherapy options for pulmonary arterial hypertension
  98. Non-Invasive Determination of Cardiac Output in Pre-Capillary Pulmonary Hypertension
  99. Nasal decongestant exposure in patients with pulmonary arterial hypertension: a pilot study: TABLE 1
  100. Criteria for diagnosis of exercise pulmonary hypertension
  101. Characteristics of Pulmonary Arterial Hypertension in Affected Carriers of a Mutation Located in the Cytoplasmic Tail of Bone Morphogenetic Protein Receptor Type 2
  102. Inspiratory muscle function, dynamic hyperinflation and exertional dyspnoea in pulmonary arterial hypertension
  103. Validation of two predictive models for survival in pulmonary arterial hypertension
  104. Systolic and Mean Pulmonary Artery Pressures
  105. Relation between left ventricular ejection time and pulmonary hemodynamics in pulmonary hypertension
  106. Chemotherapy-Induced Pulmonary Hypertension
  107. Effect of Macitentan on Hospitalizations
  108. Advances in Therapeutic Interventions for Patients With Pulmonary Arterial Hypertension
  109. Connective tissue disease associated with pulmonary arterial hypertension: management of a patient with severe haemodynamic impairment
  110. Pulmonary arterial hypertension
  111. Clinical Pharmacology of Endothelin Receptor Antagonists Used in the Treatment of Pulmonary Arterial Hypertension
  112. Pulmonary arterial hypertension in patients treated with interferon
  113. Lung and heart-lung transplantation for systemic sclerosis patients. A monocentric experience of 13 patients, review of the literature and position paper of a multidisciplinary Working Group
  114. Hypertension pulmonaire et maladies hépatiques
  115. Traitement chirurgical de l’hypertension pulmonaire post-embolique
  116. Traitement de l’hypertension artérielle pulmonaire
  117. Mechanisms of exertional dyspnoea in pulmonary veno-occlusive disease with EIF2AK4 mutations
  118. Long-term sildenafil added to intravenous epoprostenol in patients with pulmonary arterial hypertension
  119. Prognostic value of exercise pulmonary haemodynamics in pulmonary arterial hypertension
  120. The potential for macitentan, a new dual endothelin receptor antagonist, in the treatment of pulmonary arterial hypertension
  121. Current epoprostenol use in patients with severe idiopathic, heritable or anorexigen-associated pulmonary arterial hypertension: Data from the French pulmonary hypertension registry
  122. Biomarkers for the prognosis of pulmonary arterial hypertension: Holy grail or flying circus?
  123. Upfront triple combination therapy in pulmonary arterial hypertension: a pilot study
  124. EPITOME-2: An open-label study assessing the transition to a new formulation of intravenous epoprostenol in patients with pulmonary arterial hypertension
  125. Right heart failure: Toward a common language
  126. Targeted therapies in pulmonary arterial hypertension
  127. EIF2AK4 mutations cause pulmonary veno-occlusive disease, a recessive form of pulmonary hypertension
  128. Treatment Goals of Pulmonary Hypertension
  129. Proinflammatory cytokine levels are linked to death in pulmonary arterial hypertension
  130. Left Ventricular Ejection Time in Acute Heart Failure Complicating Precapillary Pulmonary Hypertension
  131. Pulmonary arterial hypertension in familial hemiplegic migraine with ATP1A2 channelopathy
  132. Inflammatory Mechanisms in HIV-Associated Pulmonary Arterial Hypertension
  133. Macitentan and Morbidity and Mortality in Pulmonary Arterial Hypertension
  134. Pharmacokinetic evaluation of sildenafil as a pulmonary hypertension treatment
  135. Pulmonary arterial hypertension
  136. Calcium-Channel Blockers in Pulmonary Arterial Hypertension
  137. Pathways in pulmonary arterial hypertension: the future is here
  138. Survival in systemic sclerosis-associated pulmonary arterial hypertension in the modern management era
  139. Independent Association of Urinary F2-Isoprostanes With Survival in Pulmonary Arterial Hypertension
  140. Pulmonary veno-occlusive disease and pulmonary capillary haemangiomatosis
  141. Hemodynamics in Pulmonary Arterial Hypertension: Current and Future Perspectives
  142. The study of risk in pulmonary arterial hypertension
  143. Treat-to-target approach in pulmonary arterial hypertension: a consensus-based proposal
  144. Computed tomography findings of pulmonary venoocclusive disease in scleroderma patients presenting with precapillary pulmonary hypertension
  145. Renal Replacement Therapy in Patients with Severe Precapillary Pulmonary Hypertension with Acute Right Heart Failure
  146. Out-of-Proportion Pulmonary Hypertension and Heart Failure with Preserved Ejection Fraction
  147. Dynamic respiratory mechanics and exertional dyspnoea in pulmonary arterial hypertension
  148. EBUS-TBNA in the differential diagnosis of pulmonary artery sarcoma and thromboembolism: Figure 1–
  149. Efficacy, safety and pharmacokinetics of bosentan in portopulmonary hypertension
  150. Pulmonary Arterial Hypertension in Patients Treated by Dasatinib
  151. Mediastinal Fibrosis Mimicking Proximal Chronic Thromboembolic Disease
  152. Pulmonary hypertension associated with benfluorex exposure
  153. Portopulmonary Hypertension
  154. L’hypertension artérielle pulmonaire associée au VIH
  155. Usefulness of first-line combination therapy with epoprostenol and bosentan in pulmonary arterial hypertension: An observational study
  156. Portopulmonary Hypertension and Hepatopulmonary Syndrome
  157. Optimal management of severe pulmonary arterial hypertension
  158. Systemic lupus erythematosus-associated PAH: is targeting inflammation the key to success?
  159. Ventilation/perfusion lung scan in pulmonary veno-occlusive disease
  160. Screening for pulmonary arterial hypertension in patients with systemic sclerosis: Clinical characteristics at diagnosis and long-term survival
  161. Pulmonary Arterial Hypertension in a Patient With Cowden Syndrome and Anorexigen Exposure
  162. Systemic sclerosis-related pulmonary hypertension associated with interstitial lung disease: Impact of pulmonary arterial hypertension therapies
  163. Treatment of pulmonary arterial hypertension with targeted therapies
  164. The association between resting and mild-to-moderate exercise pulmonary artery pressure
  165. Pulmonary hypertension related to appetite suppressants
  166. Pulmonary Hypertension in Patients With Neurofibromatosis Type I
  167. Endothelin receptor antagonists for the treatment of pulmonary arterial hypertension
  168. Prise en charge de l’hypertension artérielle pulmonaire en 2011 : les innovations depuis les recommandations ERS/ESC 2009
  169. Pulmonary veno-occlusive disease: The bête noire of pulmonary hypertension in connective tissue diseases?
  170. Current management approaches to portopulmonary hypertension
  171. Pulmonary arterial hypertension: combination therapy in the modern management era
  172. Treat-to-target strategies in pulmonary arterial hypertension: the importance of using multiple goals
  173. Pharmacokinetic evaluation of continuous intravenous epoprostenol
  174. Effects of HIV Protease Inhibitors on Progression of Monocrotaline- and Hypoxia-Induced Pulmonary Hypertension in Rats
  175. Evidence for the use of combination targeted therapeutic approaches for the management of pulmonary arterial hypertension
  176. Pulmonary veno-occlusive disease: Recent progress and current challenges
  177. Survival in Patients With Idiopathic, Familial, and Anorexigen-Associated Pulmonary Arterial Hypertension in the Modern Management Era
  178. Survival in incident and prevalent cohorts of patients with pulmonary arterial hypertension
  179. Long-term response to calcium-channel blockers in non-idiopathic pulmonary arterial hypertension
  180. Absence of influence of gender and BMPR2 mutation type on clinical phenotypes of pulmonary arterial hypertension
  181. Objectifs thérapeutiques dans l’hypertension artérielle pulmonaire
  182. Characterization of Pulmonary Arterial Hypertension Patients Walking More Than 450 m in 6 Min at Diagnosis
  183. Assessing effectiveness of pulmonary arterial hypertension therapies in daily practice
  184. Clinical Outcomes of Pulmonary Arterial Hypertension in Patients Carrying anACVRL1(ALK1) Mutation
  185. Pulmonary arterial hypertension associated with systemic sclerosis in patients with functional class II dyspnoea: mild symptoms but severe outcome
  186. Diagnostic et prise en charge de l’hypertension pulmonaire en 2009. Commentaires sur les nouvelles recommandations de l’European Society of Cardiology (ESC) et de l’European Respiratory Society (ERS)
  187. HIV-associated pulmonary arterial hypertension: survival and prognostic factors in the modern therapeutic era
  188. Maladie veino-occlusive et hémangiomatose capillaire pulmonaire
  189. Long-term outcome of systemic sclerosis-associated pulmonary arterial hypertension treated with bosentan as first-line monotherapy followed or not by the addition of prostanoids or sildenafil
  190. Implementing the ESC/ERS pulmonary hypertension guidelines: real-life cases from a national referral centre
  191. Prognostic factors of acute heart failure in patients with pulmonary arterial hypertension
  192. Noncardiothoracic nonobstetric surgery in mild-to-moderate pulmonary hypertension
  193. Is Pulmonary Arterial Hypertension Really a Late Complication of Systemic Sclerosis?
  194. Goal-oriented therapy in pulmonary veno-occlusive disease: a word of caution
  195. Pulmonary Venoocclusive Disease and Failure of Specific Therapy
  196. Phosphodiesterase type 5 inhibitors in pulmonary arterial hypertension
  197. Fatal dissection of the pulmonary artery in pulmonary arterial hypertension
  198. Idiopathic Pulmonary Arterial Hypertension and Pulmonary Veno-occlusive Disease: Similarities and Differences
  199. Pulmonary Arterial Hypertension and HIV Infection
  200. Intravenous iloprost for pulmonary arterial hypertension: still waiting for evidence
  201. Cautious epoprostenol therapy is a safe bridge to lung transplantation in pulmonary veno-occlusive disease
  202. The three-year incidence of pulmonary arterial hypertension associated with systemic sclerosis in a multicenter nationwide longitudinal study in France
  203. End Points and Clinical Trial Design in Pulmonary Arterial Hypertension
  204. Updated Evidence-Based Treatment Algorithm in Pulmonary Arterial Hypertension
  205. Cirrhosis ameliorates monocrotaline-induced pulmonary hypertension in rats
  206. Fenfluramine-like cardiovascular side-effects of benfluorex
  207. Pulmonary veno-occlusive disease
  208. Long-term effects of bosentan in patients with HIV-associated pulmonary arterial hypertension
  209. Addition of Sildenafil to Long-Term Intravenous Epoprostenol Therapy in Patients with Pulmonary Arterial Hypertension
  210. Risk factors for death and the 3-year survival of patients with systemic sclerosis: the French ItinerAIR-Sclerodermie study
  211. Portopulmonary Hypertension
  212. HIV-related pulmonary arterial hypertension: clinical presentation and management
  213. Review: Therapeutic advances in pulmonary arterial hypertension
  214. Pulmonary Veno-Occlusive Disease
  215. Clinical Outcomes of Pulmonary Arterial Hypertension in Carriers ofBMPR2Mutation
  216. Changes in exercise haemodynamics during treatment in pulmonary arterial hypertension
  217. Pulmonary arterial hypertension associated with fenfluramine exposure: report of 109 cases
  218. Immunosuppressive therapy in lupus- and mixed connective tissue disease–associated pulmonary arterial hypertension: A retrospective analysis of twenty-three cases
  219. Prevalence of HIV-related Pulmonary Arterial Hypertension in the Current Antiretroviral Therapy Era
  220. Intravenous Epoprostenol in Inoperable Chronic Thromboembolic Pulmonary Hypertension
  221. Hypertension pulmonaire postembolique
  222. Hypertension artérielle pulmonaire postembolique tumorale
  223. Pulmonary vascular abnormalities in cirrhosis
  224. Rapid Switch From Intravenous Epoprostenol to Intravenous Treprostinil in Patients With Pulmonary Arterial Hypertension
  225. Hypertension portopulmonaire
  226. Cœur pulmonaire chronique postembolique révélant une bêtathalassémie intermédiaire après splénectomie
  227. Bosentan for the treatment of pulmonary arterial hypertension associated with congenital heart defects
  228. Long term imatinib treatment in pulmonary arterial hypertension
  229. Immunosuppressive Therapy in Connective Tissue Diseases-Associated Pulmonary Arterial Hypertension
  230. Pulmonary Arterial Hypertension in France
  231. Mutations of the TGF-β type II receptorBMPR2 in pulmonary arterial hypertension
  232. Long-term outcome with first-line bosentan therapy in idiopathic pulmonary arterial hypertension
  233. Deleterious Effects of β-Blockers on Exercise Capacity and Hemodynamics in Patients With Portopulmonary Hypertension
  234. Heart rate responses during the 6-minute walk test in pulmonary arterial hypertension
  235. Occult alveolar haemorrhage in pulmonary veno-occlusive disease
  236. Clinical Challenges in Pulmonary Hypertension
  237. Pulmonary Endothelin-1 Clearance in Human Pulmonary Arterial Hypertension
  238. Splenectomy and chronic thromboembolic pulmonary hypertension
  239. Survival in patients with class III idiopathic pulmonary arterial hypertension treated with first line oral bosentan compared with an historical cohort of patients started on intravenous epoprostenol
  240. Reversibility of pulmonary arterial hypertension in HIV/HHV8-associated Castleman's disease
  241. Diagnostic et classification des hypertensions artérielles pulmonaires
  242. Génétique de l’hypertension artérielle pulmonaire: données récentes et applications pratiques
  243. Traitement chirurgical de la maladie thromboembolique pulmonaire chronique
  244. Les traitements de l’hypertension artérielle pulmonaire à l’heure de la T2A. Recommandations du groupe de travail “Maladies vasculaires pulmonaires” de la Société de pneumologie de langue française
  245. Traitement de l’hypertension artérielle pulmonaire
  246. Pulmonary hypertension associated with sarcoidosis: mechanisms, haemodynamics and prognosis
  247. Hypertension artérielle pulmonaire
  248. Human herpes virus 8 in HIV and non-HIV infected patients with pulmonary arterial hypertension in France
  249. Treatment of pulmonary arterial hypertension with bosentan: from pathophysiology to clinical evidence
  250. Long-Term Response to Calcium Channel Blockers in Idiopathic Pulmonary Arterial Hypertension
  251. Severe Pulmonary Hypertension during Pregnancy
  252. Bosentan therapy for pulmonary arterial hypertension
  253. Survival with first-line bosentan in patients with primary pulmonary hypertension
  254. Évaluation pronostique de biomarqueurs dans l’hypertension artérielle pulmonaire
  255. Bosentan for the Treatment of Human Immunodeficiency Virus–associated Pulmonary Arterial Hypertension
  256. Caractéristiques cliniques, hémodynamiques et génétiques de l’hypertension artérielle pulmonaire familiale
  257. Traitement de l'hypertension artérielle pulmonaire
  258. Treatment of Pulmonary Arterial Hypertension
  259. Pulmonary Hypertension:CT of the Chest in Pulmonary Venoocclusive Disease
  260. Diagnosis and differential assessment of pulmonary arterial hypertension
  261. Endothelin receptor antagonists in pulmonary arterial hypertension
  262. Prostanoid therapy for pulmonary arterial hypertension
  263. Prise en charge thérapeutique de l’hypertension porto-pulmonaire
  264. Automatic quantification of right ventricular function with gated blood pool SPECT
  265. Chronic thromboembolic pulmonary hypertension
  266. Traitement chirurgical de l’hypertension artérielle pulmonaire post-embolique
  267. Prise en charge thérapeutique de l’hypertension porto-pulmonaire
  268. Novel therapeutic perspectives in pulmonary arterial hypertension
  269. Effects of the Dual Endothelin Receptor Antagonist Bosentan in Patients With Pulmonary Arterial Hypertension
  270. Prognostic Factors for Survival in Human Immunodeficiency Virus–associated Pulmonary Arterial Hypertension
  271. BMPR2 germline mutations in pulmonary hypertension associated with fenfluramine derivatives
  272. Primary pulmonary hypertension: Current therapy
  273. Inhaled Iloprost for Severe Pulmonary Hypertension
  274. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension
  275. Pulmonary arterial hypertension and type-I glycogen-storage disease: the serotonin hypothesis
  276. Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial
  277. Pulmonary Arterial Hypertension: Thin-Section CT Predictors of Epoprostenol Therapy Failure
  278. Pulmonary Artery Pressure–Flow Relations after Prostacyclin in Primary Pulmonary Hypertension
  279. Hypertension artérielle pulmonaire associée aux connectivites
  280. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebocontrolled study
  281. PATHOBIOLOGY OF PULMONARY HYPERTENSION
  282. RISK FACTORS FOR PULMONARY ARTERIAL HYPERTENSION
  283. Improvement of von Willebrand Factor Proteolysis After Prostacyclin Infusion in Severe Pulmonary Arterial Hypertension
  284. Imbalance between Platelet Vascular Endothelial Growth Factor and Platelet-derived Growth Factor in Pulmonary Hypertension
  285. Severe Pulmonary Hypertension in Histiocytosis X
  286. Short-term and long-term epoprostenol (prostacyclin) therapy in pulmonary hypertension secondary to connective tissue diseases: results of a pilot study
  287. Treatment of pulmonary hypertension secondary to connective tissue diseases
  288. Primary Pulmonary Hypertension Associated With the Use of Fenfluramine Derivatives
  289. Inhaled nitric oxide as a screening agent for safely identifying responders to oral calcium-channel blockers in primary pulmonary hypertension
  290. Treatment of Severe Pulmonary Hypertension Secondary to Connective Tissue Diseases With Continuous IV Epoprostenol (Prostacyclin)
  291. Pulmonary vascular disorders in portal hypertension
  292. Clinical Significance of the Pulmonary Vasodilator Response During Short-term Infusion of Prostacyclin in Primary Pulmonary Hypertension
  293. Increased interleukin-1 and interleukin-6 serum concentrations in severe primary pulmonary hypertension.
  294. Inhaled nitric oxide as a screening vasodilator agent in primary pulmonary hypertension. A dose-response study and comparison with prostacyclin.
  295. Pneumopathie aiguë tipidique
  296. Minocycline pneumonitis and eosinophilia. A report on eight patients
  297. Minocycline Pneumonitis and Eosinophilia
  298. Auranofin in steroid dependent asthma.
  299. Prostanoid Treatment for Pulmonary Arterial Hypertension